BioMarin has settled its global patent dispute with Ascendis Pharma regarding Yuviwel, securing a significant royalty stream from Ascendis's sales of the drug in key markets. This resolution eliminates legal uncertainty for BioMarin and establishes a new revenue source.
BioMarin Pharmaceutical Inc. announced a binding agreement with Ascendis Pharma A/S to resolve all global patent and ancillary disputes concerning Ascendis's drug, Yuviwel. This settlement is significant because it removes the legal overhang and associated costs for both companies. For BioMarin, it establishes a new, recurring revenue stream through royalties: 20% of U.S. net sales and 18% of net sales in the EU, Brazil, and South Korea until May 2030, with U.S. royalties retroactive to the first commercial sale. This provides BioMarin with a long-term financial benefit and validates its intellectual property. For Ascendis, while it means paying royalties, it also clears the path for uninterrupted commercialization of Yuviwel without the threat of ongoing litigation, which can be a positive for operational stability. Traders should note the immediate positive impact on BMRN due to new revenue and reduced legal risk, while ASND faces a new cost but gains certainty.